Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older

Abstract

Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC. EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.

Efficacy of Metronomic Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer and Poor Performance Status

“…Erlotinib was found to be superior to vinorelbine in terms of objective response rate and pfs, but the difference in os was not statically significant (median survival duration: 11.6 months vs. 9.3 months respectively) 20 .…”

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review

“…In one study, the response rate favoured the egfr inhibitor 21 , and in four studies, it favoured chemotherapy 13,14,[19][20][21] . The study by Reck et al 19 found a significantly higher response rate in patients randomized to chemotherapy (p = 0.0001).…”

“…Median pfs was similar in two trials 14,18 . In one trial, pfs was longer in the egfr inhibitor group: 4.57 months for erlotinib versus 2.53 months for vinorelbine (hr: 0.6444; 95% ci: 0.4325 to 0.9601; p = 0.0308) 21 . In five trials, pfs was longer in the chemotherapy group 13,15,17,19,20 .…”

Advanced non-small cell lung cancer in elderly patients: A review

“…Although older and younger patients achieved comparable PFS, OS and RRs, older patients suffered worse toxicity due to rash, fatigue and dehydration [70] . Erlotinib performed better than vinorelbine in a subgroup of EGFR mutation positive elderly patients as shown in a prospective phase Ⅱ trial while failed to gain advantage when added to gemcitabine or compared to it in molecularly not selected elderly patients [71,72] .…”